|
|
Volumn 102, Issue 7, 2010, Pages 448-450
|
|
Stromal depletion goes on trial in pancreatic cancer.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
130 NM ALBUMIN BOUND PACLITAXEL;
130-NM ALBUMIN-BOUND PACLITAXEL;
ALBUMINOID;
ANTINEOPLASTIC AGENT;
DEOXYCYTIDINE;
DRUG DERIVATIVE;
ERLOTINIB;
GEMCITABINE;
OSTEONECTIN;
PACLITAXEL;
QUINAZOLINE DERIVATIVE;
SONIC HEDGEHOG PROTEIN;
ADENOCARCINOMA;
ANIMAL;
CLINICAL TRIAL;
DISEASE FREE SURVIVAL;
DRUG EFFECT;
HUMAN;
METABOLISM;
MORTALITY;
NOTE;
OFF LABEL DRUG USE;
PANCREAS TUMOR;
PATHOLOGY;
SIGNAL TRANSDUCTION;
SURVIVAL;
UNITED STATES;
ADENOCARCINOMA;
ALBUMINS;
ANIMALS;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS AS TOPIC;
DEOXYCYTIDINE;
DISEASE-FREE SURVIVAL;
HEDGEHOG PROTEINS;
HUMANS;
OFF-LABEL USE;
OSTEONECTIN;
PACLITAXEL;
PANCREATIC NEOPLASMS;
QUINAZOLINES;
SIGNAL TRANSDUCTION;
SURVIVAL ANALYSIS;
UNITED STATES;
|
|
EID: 77950554464
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djq113 Document Type: Note |
|
Times cited : (59)
|
|
References (0)
|
